Particulate issues cause Takeda US recall of Natpara

6 September 2019

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) is issuing a US recall for all doses of Natpara (parathyroid hormone) for Injection (25mcg, 50mcg, 75mcg, and 100mcg), with the news causing the company’s shares to dip 1.7% to 3,690 yen today.

Natpara, which came to Takeda via its recent $62 billion acquisition of Shire and generated global sales of $230 million in 2018, is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

This recall is being conducted after discussions with the Food and Drug Administration and is effective immediately due to a potential issue related to rubber particulates originating from the rubber septum of the Natpara cartridge. During the 14-day Natpara treatment period, the septum is punctured by a needle each day to obtain the daily dosage of Natpara solution. When the septum is repeatedly punctured, it is possible that small rubber fragments may detach into the cartridge.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK